CompletedNot Applicable

Dry Versus Wet Nasopharyngeal Rapid Test for the Detection of COVID-19.

Switzerland58 participantsStarted 2020-12-10

Plain-language summary

Saliva sampling could serve as an alternative non-invasive sample for SARS-CoV-2 diagnosis while rapid antigen testing (RAT) might help to mitigate the shortage of reagents sporadically encountered with RT-PCR. Thus, in the RESTART study the investigators compare antigen and RT-PCR testing methods on nasopharyngeal (NP) swabs and salivary samples. The investigators conducted a prospective observational study among COVID-19 hospitalized patients between 10th December 2020 and 1st February 2021. Paired saliva and NP samples were investigated by RT-PCR (Cobas 6800, Roche-Switzerland) and by two rapid antigen tests: One Step Immunoassay Exdia® COVID-19 Ag (Precision Biosensor, Korea) and Standard Q® COVID-19 Rapid Antigen Test (Roche-Switzerland).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Hospitalized patients aged above 18 years with confirmed SARS-CoV-2 infection by RT-PCR assay. * Provide informed consent. Exclusion Criteria: * Patient's refusal to participate in the study. * Patients with negative RT-PCR if already performed for patient's follow up as part of standard care.

What they're measuring

Diagnostic assessment

Timeframe: On the day of inclusion

Trial details

NCT IDNCT04839094

SponsorCentre Hospitalier Universitaire Vaudois

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2021-02-01

View on ClinicalTrials.gov More SARS-CoV-2 trials